TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05425056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
Study: NCT05625698

Intervention type: DRUG
Group type: OTHER
Intervention: MagTrace only
Description: see information in arm descriptions

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: MagTrace and Magseed
Description: see information in arm descriptions
Study: NCT04925349

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: blood sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: blood sample collection
Study: NCT04945187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led consultations based on electronic patient-reported outcomes
Description: The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
Study: NCT05055843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo 3D MRI
Study: NCT05800600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer
Description: Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
Study: NCT04811703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined PIPAC / IV chemotherapy treatment
Description: Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
Study: NCT06553092

Intervention type: OTHER
Intervention: Turkish Version of the Hospital for Special Surgery Shoulder Surgery Expectations Survey
Description: The Hospital for Special Surgery (HSS) Shoulder Surgery Expectations Survey is a patient-reported outcome measure designed to assess a patient's expectations before undergoing shoulder surgery. It helps clinicians understand what patients anticipate regarding pain relief, functional improvement, and overall recovery from the procedure.The HSS Shoulder Surgery Expectations Survey contains 20 questions. Each question addresses a specific aspect of shoulder function or a potential outcome that patients might expect from their surgery.Each question is scored between 1-5.It is evaluated out of a total of 80 points. A higher score indicates a greater expectation of improvement.
Study: NCT05097820

Intervention type: DEVICE
Intervention: Placement of testicular prosthesis
Description: The surgical implantation of one or two testicular prostheses on request of the patient

Intervention type: DEVICE
Intervention: Placement of testicular prosthesis
Description: The surgical implantation of one or two testicular prostheses on request of the patient
Study: NCT05259345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral SE-TAP
Description: A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the internal oblique and transversus abdominis muscles toward the lateral border of the semilunar along the costal margin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral M-TAPA
Description: A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given into the layer between the transverse abdominal muscle and the inferior plane of the costal cartilage at the midclavicular line, in the sagittal plane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral RSB
Description: A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the rectus muscle and posterior rectus sheath bilaterally.
Study: NCT04854018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Intravenous or intraparenchymal injection
Study: NCT05490186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
Study: NCT05740488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Sr
Description: 100\~150MBq(based on weight), iv, q90d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: sc, 3.6mg, q30d or 10.8mg, q90d
Study: NCT06279858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Patients will be recruited and included in the study. At baseline, a detailed medical history, and physical and neurological examination will be carried out, with all medications and medical problems documented for all participants. In the first 4 weeks, each patient will receive a weekly call to evaluate tolerability of the probiotic and any adverse events (AEs). Visit 2 will be organized after 6 weeks and final visit 3 after 12 weeks of study period. Any change in medications will also be documented during visits. The examination and documentation of AEs, will be repeated at each visit, while CGI-I will be scoring at visit 2 and final visit 3. Outcome measures will be repeated at the final followup visit at 3 months/end of treatment. Stool samples will be collected twice, at the baseline and final visits. Analyses of microbiome will be performed once, at the end of the study, when all samples are collected and sent to the selected laboratory.
Study: NCT06084832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood microsampling
Description: blood microsampling for the measure of Phosphatidylethanol

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood microsampling
Description: blood microsampling for the measure of Phosphatidylethanol
Study: NCT05820477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMS-T1D
Description: Behavioral FAMS-T1D FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Digital resources for diabetes
Description: Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
Study: NCT06072911

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercise program
Description: General exercises will be prescribed along with a specialized pelvic floor program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise program
Description: General exercises will be prescribed along with a specialized pelvic floor program
Study: NCT05820477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital resources for diabetes
Description: Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
Study: NCT06072911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General exercise
Description: A general progressive resistance exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Counseling
Description: Advice on increasing physical activity
Study: NCT05924061

Intervention type: OTHER
Intervention: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women
Description: The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia

Intervention type: OTHER
Intervention: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women
Description: The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
Study: NCT05608603

Intervention type: DIAGNOSTIC_TEST
Intervention: Portable cardiac monitor CardioQvark
Description: Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form.

Intervention type: DIAGNOSTIC_TEST
Intervention: Portable cardiac monitor CardioQvark
Description: Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory stress test
Description: Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory stress test
Description: Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer
Description: The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer
Description: The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)
Study: NCT06276569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat
Description: (1)Experimental group: Received intravenous sivelestat sodium within 6 hours of admission to the ICU. Sivelestat sodium was dissolved in 0.9% sodium chloride injection and a one-day dose (4.8mg/kg) was diluted in 50ml of 0.9% sodium chloride injection, which was then sealed for continuous intravenous administration at a rate of 0.2 mg/kg/h for seven consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2)Control group: Receiving the same dose of placebo, 50 ml of saline, were administered intravenously at a rate of 0.2 mg/kg throughout the treatment period without any discernible impact on patient's regular treatment regimen.
Study: NCT05208905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esprit BTK Device
Description: Participants will receive Esprit BTK Device
Study: NCT05323136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 for Injection
Description: single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 for Injection
Description: single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
Study: NCT06412510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Exercise Intervention: SmartGyms, band or smartphone used to scan into the TechnoGym MyWellness kiosk, which controls the TechnoGym Excite Live and Biostrength equipment. The exercise session will consist of a program that adheres to the FITT (Frequency, Intensity, Timing, and Type) exercise prescription in accordance with ACSM 2018 ACSM Roundtable recommendations for Physical Function for combined Aerobic and Resistance training.~Nutrition Intervention: 30 gm protein supplement~Supportive care/Mind-body intervention: Yoga, mindfulness practices, art therapy, and music therapy
Study: NCT06005935

Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.

Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.
Study: NCT06403007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonics plus morphology
Description: This intervention trains teachers to teach phonics plus morphology to at-risk poor readers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonics plus set-for-variability
Description: This intervention trains teachers to deliver phonics plus set-for variability to at-risk poor readers.
Study: NCT04921943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
Study: NCT04933773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement artifact - knocking
Description: 60 seconds motion artifact simulation - knocking with sensors
Study: NCT04921943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Standard of care
Study: NCT05149235

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early mobilization group
Description: Participants will perform exercises using only the cycle ergometer and ambulation. In this group, participants will be instructed to turn the pedals continuously, without any weight added to the equipment (only on 1st post-operative day) and training load will be determined by a fatigue level maintenance of 4 or 5 on the modified Borg scale with a maximum HR elevation of 20% on 2nd and 3rd post-operative days. Duration of exercise will be of 10 minutes (five minutes with the upper limbs and five minutes with the lower limbs). For the arm exercises, the individuals will be positioned with the head end of the bed raised to 60° above the horizontal, while ensuring that all the equipment responsible for measuring the patient's vital signs remained connected. For the leg exercises, the head end of the bed will be lowered to a 30° angle to provide better access to the pedals and avoid compensatory hip movements. Ambulation will be performed only on 3rd post-operative day (40 meters).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physio adventure
Description: The protocol applied to the experimental group will be the same of that applied to the early mobilization group with the use of smart move instead of cycle ergometer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants allocated to the Control group will perform respiratory physiotherapy (Flow-oriented incentive spirometer (3×15), active exercises for lower and upper limbs, with each movement being repeated 10 times in an open kinetic chain. For the upper limbs, movements of anterior flexion of the shoulder will be performed until achieving maximum range of motion, using diagonal movements starting at the contralateral iliac crest up to the maximum range of anterior flexion of the shoulder associated with supination. For the lower limbs, exercises will consist of straight leg raises, hip and knee flexion-extension exercise and ankle pumps. Sessions will be of 10 minutes duration.
Study: NCT05043350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: 107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
Study: NCT05543954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-RGD
Description: Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-RGD
Description: Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-RGD
Description: Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RGD
Description: Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
Study: NCT06020157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple Suture Technique
Description: The half of the full arch flap will be closed by the simple suture technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Suture Technique
Description: The half of the full arch flap will be closed by the continuous suture technique.
Study: NCT04590014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Precision Flow
Description: Patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Precision Flow
Description: Patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HVNI HVT2.0 Device
Description: Patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HVNI HVT2.0 Device
Description: Patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.